• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.


(CAS: )

Suppliers of C169-0381

Company Name Email Tel Country
AMEDCHEM [email protected] +862168061059 CHINA

Fax: Purity: Brand:

Inquiry Online

Salutation: *Country:
*Customer: *Company Name:
*Email: *Request quantity:

Notice: Your contact information will be sent to selected suppliers.

* Required Fields.

Background Information of C169-0381

C169-0381 is a novel cyclin-dependent kinase 8 (CDK8) inhibitor. The inhibition rate is 30.4±3.0% at 10 μM. CDK8 gene expression correlates with increased mortality in colorectal, breast, and ovarian cancers and its overexpression is essential for the proliferation of cancer cells. Due to its key roles in oncogenesis, CDK8 has recently attracted considerable attention. Inhibitors of CDK8 offer a novel strategy for the treatment of various cancers.

Solubility of C169-0381

Solubility Sources

Storage Condition of C169-0381

Storage Condition Sources

MSDS Information

MSDS Sources

Quality Control and Spectral Data

QC Reports Sources

Mechanism and Indications

Signaling Pathways Cell Cycle/DNA Damage
Target CDK
Research Area Cancer

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase

Chemical Information

M.Wt Formula CAS No. Synonyms
391.42 C22H21N3O4

Structure Information of C169-0381

Smiles C1C=CN2C(=NC(C3C=CC=C(O)C=3OC)=C2NC2C=C(OC)C(OC)=CC=2)C=1
InChI InChI=1S/C22H21N3O4/c1-27-17-11-10-14(13-18(17)28-2)23-22-20(24-19-9-4-5-12-25(19)22)15-7-6-8-16(26)21(15)29-3/h4-13,23,26H,1-3H3

Related Products

Other Form Products of C169-0381

Name CAS Formula Suppliers

Recommended Products in Same Target

Name CAS Formula Suppliers
LY2857785 1619903-54-6 C26H36N6O 12
THZ2 1604810-84-5 C31H28ClN7O2 10
Palbociclib (isethionate) 827022-33-3 C26H35N7O6S 22
CDK9-IN-6 1391855-95-0 C27H37ClN6O2 5
ML167 1285702-20-6 C19H17N3O3 15
AMG 925 1401033-86-0 C26H29N7O2 15
LDC000067 1073485-20-7 C18H18N4O3S 11
LEE011 (succinate hydrate) 1374639-79-8 C27H38N8O6X 8
LEE011 (succinate) 1374639-75-4 C27H36N8O5 9
LEE011 (hydrochloride) 1211443-80-9 C23H31ClN8O 8
LEE011 1211441-98-3 C23H30N8O 21
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 6
Wogonin 632-85-9 C16H12O5 28
1-NM-PP1 221244-14-0 C20H21N5 17
WHI-P180 211555-08-7 C16H15N3O3 13
THZ1 1604810-83-4 C31H28ClN7O2 18
Senexin A 1366002-50-7 C17H14N4 8
CDK4-IN-1 1256963-02-6 C22H29ClN8 9
Palbociclib (hydrochloride) 827022-32-2 C24H30ClN7O2 16
Purvalanol B 212844-54-7 C20H25ClN6O3 22

Recommended Products in the Same Indication

Name CAS Formula Suppliers

Chemical and Physical Properties

Appearance: Melting point:
Boiling point: Flash Point:
Water Solubility: Solubility:
Density: Merck:
BRN: Refractive Index:
Vapour: EINECS:
Optical Rotation: alpha:


[1].He LJ, et al. Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes. Bioorg Med Chem Lett. 2019 Feb 15;29(4):549-555.
With the aim of discovering novel cyclin-dependent kinase 8 (CDK8) inhibitors, a combined similarity search and molecular docking approach was employed, which led to 32 hits. Biological tests led to the discovery of several novel submicromolar inhibitors. In particular, compound C768-0769 (ZC0201) showed good CDK8 inhibitory activity, and compound ZC0201 effectively suppressed HCT-116 colorectal cancer cell proliferation by inducing G1/S transition arrest. Furthermore, modulation of phosphorylated signal transducer and activator of transcription 1 (Ser 727) (STAT1SER727), a pharmacodynamic biomarker of CDK8 activity, demonstrated that ZC0201 may cause G1/S transition arrest through CDK8 activity inhibition. Due to its good cellular activity, ZC0201 may be an ideal lead compound for further modification as a potential cancer therapeutic agent.

Tags: buy C169-0381 | C169-0381 IC50 | C169-0381 price | C169-0381 cost | C169-0381 solubility | C169-0381 purchase | C169-0381 manufacturer | C169-0381 research buy | C169-0381 order | C169-0381 MSDS | C169-0381 chemical structure | C169-0381 Storage condition | C169-0381 molecular weight | C169-0381 mw | C169-0381 datasheet | C169-0381 supplier | C169-0381 cell line | C169-0381 NMR | C169-0381 MS | C169-0381 IR | C169-0381 solubility | C169-0381 Safe information | C169-0381 Qc and Spectral Information | C169-0381 Clinical Information | C169-0381 Clinical Trial | C169-0381 Route of Synthesis | C169-0381 storage condition | C169-0381 diseases and conditions | C169-0381 flash point | C169-0381 boiling point | C169-0381 melting point | C169-0381 storage condition | C169-0381 brand